Detection of mutation-reactive t cells in patients with metastatic cancers
Ended Purchase Order Awarded Last action
- Contract number
- HHSN261201700096A
- Awardee
-
Genscript USA Inc. UEI KVLBRRAQ6UX1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $849,990
Award facts
- Opportunity
-
- N02RC7252476 Solicitation number
- FAR 6. 305 Availability of the Justification-REDACTED; Justification and Approval Award Notice · Posted Sep 28, 2017
- Acquisition of Custom Gene Synthesis and Custom Peptide Synthesis Services Award Notice · Posted Jul 29, 2017
- Contract value 100% obligated
- $849,989.66 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Piscataway, NJ 08854, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$14 | |
| Original award | $850,003 |
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Firm Fixed Price Purchase Order to GenScript USA Inc., a for-profit biotechnology company, to provide DETECTION OF MUTATION-REACTIVE T CELLS IN PATIENTS WITH METASTATIC CANCERS. The contract has a potential value of $849,989.66 and a completion date of September 21, 2019. The contract does not have a set-aside designation. GenScript USA Inc. has a history of providing customized DNA, antibodies, proteins, peptides, and other biological materials as research reagents to federal agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, and Agricultural Research Service. The company also currently holds an active Blanket Purchase Agreement with the Department of Agriculture's Animal and Plant Health Inspection Service to provide SARS-CoV-2 surrogate virus neutralization test kits.
Quick answers
Who was awarded contract HHSN261201700096A?
HHSN261201700096A was awarded to Genscript USA Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2017.
How much is contract HHSN261201700096A worth?
The government has obligated $849,990 on HHSN261201700096A.
Was contract HHSN261201700096A competed?
The extent of competition for HHSN261201700096A was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award